Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07681089
PHASE2

A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

Sponsor: Kiminori Kimura, MD

View on ClinicalTrials.gov

Summary

This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.

Official title: A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia

Key Details

Gender

MALE

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

7

Start Date

2026-10-01

Completion Date

2028-03-31

Last Updated

2026-10-05

Healthy Volunteers

No

Conditions

Interventions

DRUG

Foscenvivint

Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks

Locations (4)

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

National Hospital Organization Sendai Medical Center

Sendai, Miyagi, Japan

National Hospital Organization Osaka National Hospital

Osaka, Osaka, Japan

Tokyo Metropolitan Komagome Hospital

Bunkyo-Ku, Tokyo, Japan